Mitochondrial N-formyl methionine peptides contribute to exaggerated neutrophil activation in patients with COVID-19
Neutrophil dysregulation is well established in COVID-19. However, factors contributing to neutrophil activation in COVID-19 are not clear. We assessed if N-formyl methionine (fMet) contributes to neutrophil activation in COVID-19. Elevated levels of calprotectin, neutrophil extracellular traps (NETs) and fMet were observed in COVID-19 patients (n = 68), particularly in critically ill patients, as compared to HC (n = 19, p < 0.0001). Of note, the levels of NETs were higher in ICU patients with COVID-19 than in ICU patients without COVID-19 (p < 0.05), suggesting a prominent contribution of NETs in COVID-19. Additionally, plasma from COVID-19 patients with mild and moderate/severe symptoms induced in vitro neutrophil activation through fMet/FPR1 (formyl peptide receptor-1) dependent mechanisms (p < 0.0001). fMet levels correlated with calprotectin levels validating fMet-mediated neutrophil activation in COVID-19 patients (r = 0.60, p = 0.0007). Our data indicate that fMet is an important factor contributing to neutrophil activation in COVID-19 disease and may represent a potential target for therapeutic intervention.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Virulence - 14(2023), 1 vom: 10. Dez., Seite 2218077 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kuley, Runa [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.05.2023 Date Revised 17.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/21505594.2023.2218077 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357508793 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357508793 | ||
| 003 | DE-627 | ||
| 005 | 20240417232138.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/21505594.2023.2218077 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1378.xml |
| 035 | |a (DE-627)NLM357508793 | ||
| 035 | |a (NLM)37248708 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kuley, Runa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mitochondrial N-formyl methionine peptides contribute to exaggerated neutrophil activation in patients with COVID-19 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.05.2023 | ||
| 500 | |a Date Revised 17.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Neutrophil dysregulation is well established in COVID-19. However, factors contributing to neutrophil activation in COVID-19 are not clear. We assessed if N-formyl methionine (fMet) contributes to neutrophil activation in COVID-19. Elevated levels of calprotectin, neutrophil extracellular traps (NETs) and fMet were observed in COVID-19 patients (n = 68), particularly in critically ill patients, as compared to HC (n = 19, p < 0.0001). Of note, the levels of NETs were higher in ICU patients with COVID-19 than in ICU patients without COVID-19 (p < 0.05), suggesting a prominent contribution of NETs in COVID-19. Additionally, plasma from COVID-19 patients with mild and moderate/severe symptoms induced in vitro neutrophil activation through fMet/FPR1 (formyl peptide receptor-1) dependent mechanisms (p < 0.0001). fMet levels correlated with calprotectin levels validating fMet-mediated neutrophil activation in COVID-19 patients (r = 0.60, p = 0.0007). Our data indicate that fMet is an important factor contributing to neutrophil activation in COVID-19 disease and may represent a potential target for therapeutic intervention | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, P.H.S. | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a N-formyl methionine peptide | |
| 650 | 4 | |a clinical biomarkers | |
| 650 | 4 | |a mitochondrial peptides | |
| 650 | 4 | |a neutrophils | |
| 650 | 4 | |a systemic inflammation | |
| 650 | 7 | |a Methionine |2 NLM | |
| 650 | 7 | |a AE28F7PNPL |2 NLM | |
| 650 | 7 | |a Peptides |2 NLM | |
| 650 | 7 | |a N-Formylmethionine |2 NLM | |
| 650 | 7 | |a 4289-98-9 |2 NLM | |
| 650 | 7 | |a Racemethionine |2 NLM | |
| 650 | 7 | |a 73JWT2K6T3 |2 NLM | |
| 650 | 7 | |a Leukocyte L1 Antigen Complex |2 NLM | |
| 700 | 1 | |a Duvvuri, Bhargavi |e verfasserin |4 aut | |
| 700 | 1 | |a Wallin, Jeffrey J |e verfasserin |4 aut | |
| 700 | 1 | |a Bui, Nam |e verfasserin |4 aut | |
| 700 | 1 | |a Adona, Mary Vic |e verfasserin |4 aut | |
| 700 | 1 | |a O'Connor, Nicholas G |e verfasserin |4 aut | |
| 700 | 1 | |a Sahi, Sharon K |e verfasserin |4 aut | |
| 700 | 1 | |a Stanaway, Ian B |e verfasserin |4 aut | |
| 700 | 1 | |a Wurfel, Mark M |e verfasserin |4 aut | |
| 700 | 1 | |a Morrell, Eric D |e verfasserin |4 aut | |
| 700 | 1 | |a Liles, W Conrad |e verfasserin |4 aut | |
| 700 | 1 | |a Bhatraju, Pavan K |e verfasserin |4 aut | |
| 700 | 1 | |a Lood, Christian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Virulence |d 2010 |g 14(2023), 1 vom: 10. Dez., Seite 2218077 |w (DE-627)NLM199668515 |x 2150-5608 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g number:1 |g day:10 |g month:12 |g pages:2218077 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/21505594.2023.2218077 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |e 1 |b 10 |c 12 |h 2218077 | ||